Oncogenic alterations in ERBB2/HER2represent potential therapeutic targets across tumors from diverse anatomic sites of origin

Oncologist

Volumn 20, Issue 1, 2015, Pages 7-12

  Chmielecki, Juliann ^a   Ross, Jeffrey S ^b   Wang, Kai ^a   Frampton, Garrett M ^a   Palmer, Gary A ^a   Ali, Siraj M ^a   Palma, Norma ^a   Morosini, Deborah ^a   Miller, Vincent A ^a   Yelensky, Roman ^a   Lipson, Doron ^a   Stephens, Philip J ^a  

^a FOUNDATION MEDICINE   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Antibodies; High throughput nucleotide sequencing; Humanized; Lapatinib; Monoclonal; Mutation; Pertuzumab; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA UROGASTRONE; ERBB2 PROTEIN, HUMAN; LAPATINIB; MONOCLONAL ANTIBODY; PERTUZUMAB; QUINAZOLINE DERIVATIVE; TRASTUZUMAB;

AMINO ACID SUBSTITUTION; ARTICLE; BILE DUCT CARCINOMA; BREAST CANCER; DUODENUM CARCINOMA; ESOPHAGUS CANCER; GENE DELETION; GENE DOSAGE; GENE EXPRESSION; GENE FREQUENCY; GENE INSERTION; GENE MUTATION; GENE REARRANGEMENT; GENETIC SCREENING; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NEXT GENERATION SEQUENCING; PERITONEAL CARCINOMA; PERITONEAL DISEASE; POINT MUTATION; PRIORITY JOURNAL; SOLID TUMOR; STOMACH CANCER; TRANSITIONAL CELL CARCINOMA; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; COPY NUMBER VARIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SEQUENCING; IMMUNOLOGY; MUTATION; STOMACH NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; DNA COPY NUMBER VARIATIONS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MUTATION; QUINAZOLINES; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TRASTUZUMAB;

EID: 84921279242     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0234     Document Type: Article

References (45)

1. National Research Council (U.S.). Committee on A Framework for Developing a New Taxonomy of Disease. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Washington, D.C.: National Academies Press, 2011.
2. Chmielecki J, Meyerson M. DNA sequencing of cancer: What have we learned? Annu Rev Med 2014;65:63-79.
3. Weinstein IB. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002;297: 63-64.
4. Sequist LV, Yang JC, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinomawith EGFR mutations. J Clin Oncol 2013;31:3327-3334.
5. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
6. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-967.
7. Stern HM. Improving treatment of HER2-positive cancers: Opportunities and challenges. Sci Transl Med 2012;4:127-2. doi: 10.1126/scitranslmed.3001539
8. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353: 1659-1672.
9. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-1684.
10. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl JMed 2001;344:783-792.
11. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010;376: 687-697.
12. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743.
13. Awada A, Dirix L, Manso Sanchez L et al. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol 2013;24:109-116.
14. Mazieres J, Peters S, Lepage B et al. Lung cancer that harbors an HER2 mutation: Epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013;31:1997-2003.
15. Hicks DG, Kulkarni S.Trastuzumab as adjuvant therapy for early breast cancer: The importance of accurate human epidermal growth factor receptor 2 testing. Arch Pathol Lab Med 2008;132: 1008-1015.
16. Ruschoff J, Dietel M, Baretton G et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010;457:299-307.
17. Gutierrez C, Schiff R. HER2: Biology, detection, and clinical implications. Arch Pathol LabMed 2011; 135:55-62.
18. Stephens P, Hunter C, Bignell G et al. Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature 2004;431:525-526.
19. Shigematsu H, Takahashi T, Nomura M et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005;65: 1642-1646.
20. Buttitta F, Barassi F, Fresu G et al. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: Mutations aremainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer 2006;119:2586-2591.
21. Bose R, Kavuri SM, Searleman AC et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013;3: 224-237.
22. Ross JS, Wang K, Sheehan CE et al. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations. Clin Cancer Res 2013;19: 2668-2676.
23. Ross JS, Wang K, Gay LM et al. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Clin Cancer Res 2014;20:68-75.
24. Greulich H, Kaplan B, Mertins P et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci USA 2012;109:14476-14481.
25. Shimamura T, Ji H, Minami Y et al. Non-smallcell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptorand ERBB2 inhibitorHKI-272. Cancer Res 2006;66:6487-6491.
26. Kancha RK, von Bubnoff N, Bartosch N et al. Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib. PLoS One 2011;6: e26760.
27. Kaidar-Person O, Billan S, Kuten A. Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: Case report and literature review. Med Oncol 2012;29:704-706.
28. Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 2006;354: 2619-2621.
29. Ali SM, Alpaugh RK, Downing SR et al. Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy. J Clin Oncol 2014;32:e88-e91.
30. Frampton GM, Fichtenholtz A, Otto GA et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31:1023-1031.
31. Lipson D, Capelletti M, Yelensky R et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012;18:382-384.
32. Trowe T, Boukouvala S, Calkins K et al. EXEL-7647 inhibits mutantforms of ErbB2 associated with lapatinib resistance and neoplastic transformation. Clin Cancer Res 2008;14:2465-2475.
33. Minami Y, Shimamura T, Shah K et al. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene 2007;26:5023-5027.
34. Wang SE, Narasanna A, Perez-Torres M et al. HER2kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006;10:25-38.
35. Ross JS, Wang K, Al-Rohil RN et al. Advanced urothelial carcinoma: Next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod Pathol 2014;27:271-280.
36. Nielsen DL, Kumler I, Palshof JA et al. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Breast 2013;22:1-12.
37. Murphy CG, Morris PG. Recent advances in novel targeted therapies for HER2-positive breast cancer. Anticancer Drugs 2012;23:765-776.
38. Fornaro L, Lucchesi M, Caparello C et al. Anti-HER agents in gastric cancer: From bench to bedside. Nat Rev Gastroenterol Hepatol 2011;8: 369-383.
39. Arcila ME, Chaft JE, Nafa K et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 2012;18: 4910-4918.
40. Lee JW, Soung YH, Seo SH et al. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res 2006;12:57-61.
41. Forbes SA, Bindal N, Bamford S et al. COSMIC: Mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011;39:D945-D950.
42. Cerami E, Gao J, Dogrusoz U et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401-404.
43. Gao J, Aksoy BA, Dogrusoz U et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6:pl1.
44. Liang Z, Zhang J, Zeng X et al. Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas. BMC Cancer 2010;10:376.
45. Vornicova O, Hershkovitz D, Yablonski-Peretz T et al. Treatment of metastatic extramammary Paget’s disease associated with adnexal adenocarcinoma, with anti-HER2 drugs based on genomic alteration ERBB2 S310F. The Oncologist 2014;19: 1006-1007.